
|Articles|March 1, 2008
Accommodating IOL's new design shows benefits
Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Midyear cataract check-in: What 2026 has brought to the OR and beyond
2
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
3
Recognizing biomarkers of Alzheimer Disease using OCTA
4
Durability With Aflibercept 8 mg in Retinal Vascular Diseases
5





















